Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 5 for:    F-18 RGD-K5
Previous Study | Return to List | Next Study

Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5

This study has been completed.
Sponsor:
Information provided by:
Siemens Molecular Imaging
ClinicalTrials.gov Identifier:
NCT00743353
First received: August 26, 2008
Last updated: January 29, 2009
Last verified: January 2009

August 26, 2008
January 29, 2009
August 2008
January 2009   (final data collection date for primary outcome measure)
To collect bio-distribution data to calculate dosimetry values in normals and obtain and evaluate PET images in cancer subjects for resolution of [F-18]RGD-K5 [ Time Frame: imaging study-participation only days ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00743353 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5
An Exploratory, Multi-Center, Open Label, Non-Randomized Study of F-18 RGD-K5

The purpose of this research study is to get information from volunteers without cancer and patients with cancer who have received a new investigational study agent called, "[F-18] RGDK5," to evaluate biodistribution and dosimetry for the study agent and determine F-18 RGD-K5 uptake in angiogenic tumor. the system.

[F-18]RGD-K5 is being investigated as a diagnostic radiopharmaceutical for the detection and localization of angiogenesis tissue or lesions supporting the application and role of integrins in anti-angiogenic therapies to benefit patients with cancer and inflammatory diseases.

The primary objectives of this exploratory study are:

  • To gain information on biodistribution of [F-18]RGD-K5, and to evaluate the PET images with [F-18]RGD-K5 for resolution, signal to background ratio and for the detection and localization of angiogenesis tissue. This Exploratory Investigational New Drug (EIND) study is designed to obtain preliminary imaging and fundamental biodistribution, metabolism and safety information to demonstrate early proof of concept. The information collected under this study will not be used for diagnostic purposes, to assess the subject's response to therapy, or for clinical management for the subject.
Interventional
Phase 0
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
  • Sarcoma
  • Melanoma
  • Lung Cancer
  • Breast Cancer
  • High Grade Gliomas
Drug: F-18 RGD-K5
Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
Experimental: A
16 subjects to be enrolled; Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
Intervention: Drug: F-18 RGD-K5
Doss M, Kolb HC, Zhang JJ, Bélanger MJ, Stubbs JB, Stabin MG, Hostetler ED, Alpaugh RK, von Mehren M, Walsh JC, Haka M, Mocharla VP, Yu JQ. Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans. J Nucl Med. 2012 May;53(5):787-95. doi: 10.2967/jnumed.111.088955. Epub 2012 Apr 12.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
16
January 2009
January 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

For Normal Volunteers

  • Subject is ≥ 18 years old at the time of investigational product administration (Subject is male or female of any race / ethnicity)
  • Subject or subject's legally acceptable representative provides informed consent
  • Subject is capable of complying with study procedures
  • Subject is capable of communicating with study personnel

For Cancer Subjects (same first four bullets as 'normals')

  • Subject must have had a diagnostic imaging study and is suspected of having a primary or metastatic tumor(s) ( > 2 cm, except breast tumor)-sarcoma; melanoma; lung cancer [including small cell and non-small cell lung cancer (NSCL)]; high grade glioma (including glioblastoma multi-forms), anaplastic astrocytoma, and anaplastic oligodendroglioma; breast carcinomas, and head and neck tumors, including laryngeal squamous cell carcinoma
  • Subject is scheduled to have a clinical [F-18]FDG PET scan within ± 7 days (with no interventions between the two PET scans) of the investigational, [F-18]RGD-K5 PET scan
  • Subject is scheduled to undergo resection or biopsy of the target tumor as a result of routine clinical treatment
  • Subject has not received any anti-angiogenic agents (e.g. bevacizumab, sorafenib, sunitinib) within 10 days prior to PET/CT imaging
  • Subject has laboratory test results within the following ranges:
  • AST(SGOT)/ALT(SGPT) ≤ 2.5 x institutional upper limits of normal
  • Serum creatinine ≤ 1.5 institutional upper limits of normal
  • Platelet count of > 75,000x106/L
  • Hemoglobin value of > 9 g/dL
  • ANC > 1.2 x 106 /mL

Exclusion Criteria 'Normals':

  • Subject is < 18 at the time of investigational product administration
  • Female subject is pregnant or nursing:
  • by testing on site at the institution (serum or urine ßHCG) within 24 hours prior to the investigational product administration
  • Subject is unable to remain still for duration of imaging procedure
  • Subject has a history of renal disease
  • Subject has previously received [F-18]RGD-K5 at any time, or any other investigational product in the past 30 days or will receive any other investigational product within 48 hours after the [F-18]RGD-K5 injection
  • Subject has not been involved in an investigative, radioactive research procedure or therapeutic procedure within the past 6 months
  • Subject has any other condition or personal circumstance including severe claustrophobia, severe dyspnea, severe back pain etc, that, in the judgment of the investigator, might interfere with the collection of complete good quality data
  • Subject has a history of significant prescription or non-prescription drug, or alcohol abuse, including but not limited to marijuana, cocaine, heroin or derivatives.

For Cancer Subjects (first three bullets the same as 'normals')

  • Subject is < 18 at the time of investigational product administration
  • Female subject is pregnant or nursing:
  • by testing on site at the institution (serum or urine ßHCG)
  • Subject is unable to remain still for duration of imaging procedure
  • Subject has known hyper or hypo-coagulation syndromes. (e.g., Protein C, S deficiency, Hemophilia A/B/C, Factor-V Leiden, etc.)
  • Subject has previously received [F-18]RGD-K5 at any time, or any other investigational product in the past 30 days or will receive any other investigational product within 48 hours after the [F-18]RGD-K5 injection.
  • Subject has inadequate tumor size (< 2 cm , except for breast tumor) or volume to allow for biopsy
  • Subject has any other condition or personal circumstance including severe claustrophobia, severe dyspnea, severe back pain etc, that, in the judgment of the investigator, might interfere with the collection of complete good quality data
  • Subject has a history of significant prescription or non-prescription drug, or alcohol abuse, including but not limited to marijuana, cocaine, heroin or derivatives.
Both
Not Provided
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00743353
K5-100
No
James Zhang, MD, PhD, MBA, Senior Director, Medical Monitor, Global Head of Clinical Development
Siemens Molecular Imaging
Not Provided
Principal Investigator: Michael Yu, MD Fox Chase Cancer Center, Dept of Nuclear Medicine, 333 Cottman Ave, Phila, PA 19111
Siemens Molecular Imaging
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP